Sabril

Indicated For

Infantile spasms, Refractory complex partial seizures

About This Medication

# SHARE Patient Assistance Program Patient Guide: How to Get Sabril at Low or No Cost ## About This Program The **SHARE Patient Assistance Program**, administered by Lundbeck, is designed to help eligible patients access **Sabril (vigabatrin)** at reduced or no cost. Sabril is an antiepileptic medication used to treat infantile spasms (West syndrome) and as adjunctive therapy for refractory focal seizures. If you're struggling to afford this medication, this program may help you obtain it without the full out-of-pocket expense. ## Who Qualifies for SHARE? While specific income thresholds are not publicly detailed, the SHARE program is primarily designed for: - **Commercially insured patients** who face financial hardship in affording their medication - Patients with **limited financial resources** who cannot access Sabril through their insurance - Individuals who meet Lundbeck's eligibility criteria based on household income and financial need The program evaluates each application individually, considering your household income, family size, and ability to pay. Even if you have insurance, you may qualify if your out-of-pocket costs are prohibitively high. ## Income Eligibility Lundbeck does not publicly specify exact income thresholds for the SHARE program. However, eligibility is typically based on: | Factor | Details | |--------|----------| | **Household Income** | Evaluated on a case-by-case basis; generally targets patients with limited financial resources | | **Family Size** | Considered when determining financial need | | **Insurance Status** | Program primarily serves commercially insured patients facing affordability barriers | | **Medical Need** | Valid prescription from a healthcare provider required | To learn your specific eligibility, contact the program directly at **(888) 457-4273**. Program representatives can discuss your financial situation confidentially and determine whether you qualify. ## Insurance Requirements The SHARE program is **primarily designed for commercially insured patients**. However: - You do **not** need to have insurance to apply - If you have insurance, the program may coordinate with your plan - Medicare and Medicaid patients should contact the program to discuss eligibility, as coverage varies - Patients without any insurance may still qualify based on financial need Regardless of your insurance status, having a valid prescription from your healthcare provider is essential. ## How to Apply for SHARE ### Step 1: Gather Required Documents Before calling, prepare: - Your **valid prescription** for Sabril from your doctor - **Proof of financial need** (examples include recent tax returns, pay stubs, bank statements, or proof of income) - Your **insurance information** (if applicable) - Your **contact information** and basic demographic details ### Step 2: Call the Program Contact the SHARE Patient Assistance Program at: **Phone: (888) 457-4273** Program representatives are available to answer questions and guide you through the application process. They can explain eligibility requirements specific to your situation and help you understand what documentation you'll need. ### Step 3: Complete Your Application During your call, you'll provide: - Personal and household information - Details about your financial situation - Your prescription and prescriber information - Insurance details (if applicable) ### Step 4: Submit Documentation After your initial call, submit your required financial documentation as instructed by the program representative. This typically includes proof of income and proof of financial need. ### Step 5: Wait for Approval The program will review your application and contact you with a decision. Processing timelines are not publicly specified, so ask the program representative for an estimated timeframe when you apply. ### Step 6: Receive Your Medication Once approved, the program will provide instructions on how to receive your Sabril. Delivery methods are not publicly detailed, so confirm this with the program when you're approved. ## Timeline and What to Expect - **Application Call**: 15-30 minutes - **Documentation Submission**: Within 5-10 business days of your call - **Review and Decision**: Timeline not specified; ask when you apply - **Medication Delivery**: Method and timeline to be confirmed upon approval To avoid delays, ensure all required documents are complete and accurate before submitting. ## What If Your Application Is Denied? If you're denied assistance: 1. **Ask for specific reasons** why you didn't qualify 2. **Explore alternatives**: - Discuss generic vigabatrin options with your doctor (if available) - Ask your healthcare provider about other seizure medications that may be more affordable - Contact patient advocacy organizations for seizure disorders for additional resources - Inquire about manufacturer coupons or discount programs - Check if you qualify for state Medicaid programs 3. **Reapply if circumstances change** (e.g., if your income decreases or insurance coverage changes) ## Reauthorization and Refills Specific details about reauthorization requirements and refill processes are not publicly available. When you're approved, ask the program: - How long your assistance lasts - Whether you need to reapply annually or at other intervals - How to request refills - What happens if your financial situation improves ## Important Disclaimer This guide provides general information about the SHARE Patient Assistance Program based on publicly available information. Program details, eligibility criteria, and requirements may change. **This assistance is not insurance** and does not replace your health insurance coverage. For the most current and accurate information, contact the SHARE program directly at **(888) 457-4273**. Your healthcare provider can also help you understand whether this program is appropriate for your situation and can assist with the application process. Always work with your doctor to ensure you have consistent access to Sabril and that your seizure management plan remains effective.

Program information last verified: March 25, 2026